All In Biotech

Drug Trial Radar · NCT07900243

A Clinical Study Comparing the Efficacy and Safety of Befotertinib Versus Icotinib in Patients With Previously Untreated EGFR-sensitive Mutation-positive Non-small Cell Lung Cancer With ECOG Score ≥2

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Dec 31, 2028

Study completion Dec 31, 2030

Sponsor

Lead sponsor
Zhou ChengzhiAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, open-label, parallel-controlled clinical trial. It is designed to evaluate the efficacy and safety of Befotertinib versus Icotinib as first-line treatment in patients with previously untreated EGFR-sensitive mutation-positive locally advanced or metastatic non-small cell lung cancer with ECOG score ≥2.

Conditions

  • Locally Advanced or Metastatic Non-small Cell Lung Cancer With Previously Untreated EGFR-sensitive Mutations and ECOG Performance Status Score ≥2

Interventions

  • BefotertinibDrug

    befortertinib

  • IcotinibDrug

    Icotinib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFSTime frame: 9 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.